Bipolar I Disorder

Neurology·MeSH: Bipolar Disorder

Prevalence

463.1 / 100K

Incidence

32.5 / 100K/yr

27 drugs in development·20 companies·12 clinical trials

Drug Pipeline by Phase

Approved(18)

Drug	Company
fanapt	Vanda Pharmaceuticals Inc. (VNDA)
lamotrigine	Teva Pharmaceutical Industries Limited (TEVA)
lurasidone	DR REDDYS LABORATORIES LTD (RDY)
LYBALVI	Alkermes plc. (ALKS)
RISPERDAL CONSTA	Alkermes plc. (ALKS)
risperidone	SUNSET ISLAND GROUP (SUN)
risperidone	ANI PHARMACEUTICALS INC (ANIP)
risperidone	Prestige Consumer Healthcare Inc. (PBH)
risperidone	AlphaTON Capital Corp (ATON)
risperidone	Synthorx, Inc. (THOR)
risperidone	PRECISION BIOSCIENCES INC (DTIL)
risperidone	NANOMIX CORP (BTHI)
risperidone	DR REDDYS LABORATORIES LTD (RDY)
risperidone	Aptinyx Inc. (APTX)
risperidone	Amneal Pharmaceuticals, Inc. (AMRX)
risperidone	LANNETT CO INC (LCI)
risperidone	REATA PHARMACEUTICALS INC (RETA)
uzedy	Teva Pharmaceutical Industries Limited (TEVA)

Phase 3(4)

Drug	Company
bxcl501 sublingual film	BioXcel Therapeutics, Inc. (BTAI)
bysanti	Vanda Pharmaceuticals Inc. (VNDA)
nbi-1117568	NEUROCRINE BIOSCIENCES INC (NBIX)
OLZ/SAM	Alkermes plc. (ALKS)

Phase 2(2)

Drug	Company
Icalcaprant	AbbVie Inc. (ABBV)
lb-102	LB PHARMACEUTICALS INC (LBRX)

Phase 1/Phase 2(3)

BioSniper tracks 27 drugs in development for Bipolar I Disorder across 20 companies.

There are 12 clinical trials targeting Bipolar I Disorder tracked by BioSniper.

The estimated prevalence of Bipolar I Disorder is approximately 463.1 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.